Sprout Pharmaceuticals

Reuters reported after Monday's market close that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plans on cutting its sales force for Addyi, a treatment aimed at female sexual dysfunction. Reuters noted that an outside sales force handles sales for Addyi, which fell under Valeant's corporate...

On Tuesday, the FDA approved Flibanserin, a product developed by privately held Sprout Pharmaceuticals, as the first pharmacologic therapy for female sexual dysfunction. However, clinical evidence supporting the approval is limited, and the consent comes with a Black Box warning, REMS, and three...